Mirum Pharmaceuticals (MEX:MIRM) Piotroski F-Score: 4 (As of Jul. 11, 2026) — Near Median


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN812.06
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Piotroski F-Score?

Mirum Pharmaceuticals MEX:MIRM 46 Piotroski F-Score is 4 as of Jul. 11, 2026, which is at its 10-year median of 4.00. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN812.06. The stock has 5 warning signs investors should review. Among 1,332 Biotechnology companies, Mirum Pharmaceuticals ranks better than 73.8% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mirum Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Mirum Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

MEX:MIRM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 6
Current: 4

During the past 8 years, the highest Piotroski F-Score of Mirum Pharmaceuticals was 6. The lowest was 3. And the median was 4.

Mirum Pharmaceuticals  (MEX:MIRM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Mirum Pharmaceuticals Piotroski F-Score Related Terms


Mirum Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Piotroski F-Score Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 3.00 3.00 5.00 6.00

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 6.00 6.00 6.00 4.00

MEX:MIRM vs RYTM, SYRE, PTGX: Piotroski F-Score Comparison

For the Biotechnology subindustry, Mirum Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Piotroski F-Score falls into.


MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -110.358 + 53.29 + -103.173 + -14248.628 = MXN-14,409 Mil.
Cash Flow from Operations was 226.704 + 727.916 + 109.241 + -4125.215 = MXN-3,061 Mil.
Revenue was 2406.089 + 2439.962 + 2681.625 + 2883.104 = MXN10,411 Mil.
Gross Profit was 1965.091 + 1971.506 + 2172.712 + 2363.672 = MXN8,473 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(14121.17 + 13666.704 + 14402.307 + 15175.438 + 16065.621) / 5 = MXN14686.248 Mil.
Total Assets at the begining of this year (Mar25) was MXN14,121 Mil.
Long-Term Debt & Capital Lease Obligation was MXN5,796 Mil.
Total Current Assets was MXN10,268 Mil.
Total Current Liabilities was MXN4,920 Mil.
Net Income was -451.371 + -280.291 + -496.157 + -300.265 = MXN-1,528 Mil.

Revenue was 1426.678 + 1779.55 + 2073.349 + 2282.828 = MXN7,562 Mil.
Gross Profit was 1056.117 + 1369.874 + 1598.256 + 1811.921 = MXN5,836 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(10820.128 + 12105.081 + 13151.014 + 13989.044 + 14121.17) / 5 = MXN12837.2874 Mil.
Total Assets at the begining of last year (Mar24) was MXN10,820 Mil.
Long-Term Debt & Capital Lease Obligation was MXN6,455 Mil.
Total Current Assets was MXN8,405 Mil.
Total Current Liabilities was MXN2,610 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mirum Pharmaceuticals's current Net Income (TTM) was -14,409. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mirum Pharmaceuticals's current Cash Flow from Operations (TTM) was -3,061. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-14408.869/14121.17
=-1.0203736

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-1528.084/10820.128
=-0.14122606

Mirum Pharmaceuticals's return on assets of this year was -1.0203736. Mirum Pharmaceuticals's return on assets of last year was -0.14122606. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Mirum Pharmaceuticals's current Net Income (TTM) was -14,409. Mirum Pharmaceuticals's current Cash Flow from Operations (TTM) was -3,061. ==> -3,061 > -14,409 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=5796.179/14686.248
=0.39466711

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=6454.808/12837.2874
=0.50281713

Mirum Pharmaceuticals's gearing of this year was 0.39466711. Mirum Pharmaceuticals's gearing of last year was 0.50281713. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=10268.469/4919.753
=2.08719198

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=8404.597/2609.996
=3.22015704

Mirum Pharmaceuticals's current ratio of this year was 2.08719198. Mirum Pharmaceuticals's current ratio of last year was 3.22015704. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Mirum Pharmaceuticals's number of shares in issue this year was 58.851. Mirum Pharmaceuticals's number of shares in issue last year was 48.889. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=8472.981/10410.78
=0.81386611

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5836.168/7562.405
=0.77173439

Mirum Pharmaceuticals's gross margin of this year was 0.81386611. Mirum Pharmaceuticals's gross margin of last year was 0.77173439. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=10410.78/14121.17
=0.73724628

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=7562.405/10820.128
=0.69892011

Mirum Pharmaceuticals's asset turnover of this year was 0.73724628. Mirum Pharmaceuticals's asset turnover of last year was 0.69892011. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mirum Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Piotroski F-Score of 4 as of Jul. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mirum Pharmaceuticals and its competitors. This is near median its historical median of 4.00. Over the past decade, Mirum Pharmaceuticals' Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Mirum Pharmaceuticals ranks #349 out of 1332 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Mirum Pharmaceuticals' Piotroski F-Score too high?
Mirum Pharmaceuticals' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Mirum Pharmaceuticals' value of 4 is 33.3% above this industry median. Based on the distribution chart, Mirum Pharmaceuticals ranks #349 out of 1332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Piotroski F-Score compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #349 out of 1332 companies for Piotroski F-Score. This puts Mirum Pharmaceuticals in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Mirum Pharmaceuticals' value of 4 is 33.3% above this benchmark. Historically, Mirum Pharmaceuticals' own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Mirum Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mirum Pharmaceuticals's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mirum Pharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mirum Pharmaceuticals's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Piotroski F-Score of 4. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Piotroski F-Score is 4 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.

Key valuation signals for MEX:MIRM:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
  • GF Score™: 46/100 with 5 warning signs
  • Industry Position: 33.3% above the Biotechnology median (#349 of 1332)

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN812.06
GF Value